Fig. 4. (A) After first injection of high-dose bevacizumab. (B) After second injection of high-dose bevacizumab, submacular hemorrhage and subretinal fluid persisted. (C) After third injection of high-dose bevacizumab, subretinal fluid decreased. (D) After forth injection of high-dose bevacizumab, inner retinal cysts remained, but subretinal fluid was not observed. (E) After fifth injection of high-dose bevacizumab, macular edema decreased and subretinal fluid was not observed. (F) At 3 month after the fifth injection, the macular structure recovered and there was no recurrence.

J Retin 2021;6:150-4 https://doi.org/10.21561/jor.2021.6.2.150

© 2021 J Retin